CROs & CDMOs
With the vaccine business made lucrative by the COVID-19 pandemic, and more and more ATMPs in clinical testing, providers such as CDMOs are also expanding their capacity to produce vectors and alternative tools for delivery. Add to this: After the first eleven approvals of gene therapies for rare diseases and cell therapies for blood cancer, there are a large number of candidates being tested in clinical trials. Digitalisation is becoming increasingly important for both CDMOs and CROs.
In this issue:
- Technology expansion
- Interview: Christian Schetter, CSO, Rentschler Biopharma SE
- CRO of the future
- Innovation in drug development
- Bringing virotherapy forward
- Interview: Dimitrios Wagner, Charité
- CB21 R&D: CDMO for endocannabinoids
- Vector BioPharma: the future of gene delivery